8-K: Rein Therapeutics Secures $2.5M Unsecured Note

Rein Therapeutics, Inc. has secured a $2.5 million unsecured promissory note from Funicular Funds, LP, with a 20% original issue discount and a maturity date by June 30, 2026, or earlier upon a significant future capital raise.

Summary

• Rein Therapeutics, Inc. (the Company) entered into a Securities Purchase Agreement with Funicular Funds, LP (the Purchaser) on January 15, 2026.
• The Company issued and sold an unsecured promissory note (the Note) with an original principal amount of $2,500,000 to Funicular Funds, LP.
• The cash purchase price for the Note was $2,000,000, which includes a 20% original issue discount.
• The Note bears a simple interest rate of zero percent (0%) per annum.
• The maturity date for all interest and principal is the earlier of June 30, 2026, or the closing date of the next issuance and sale of securities by the Company generating gross proceeds of at least $10,000,000 (excluding the proceeds from this Note).
• The Company's obligations under the Note are unsecured.
• The Note was sold in a private placement, exempt from registration requirements under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.

Sentiment

Score: 4

Explanation: While securing funding is positive for immediate liquidity, the 20% original issue discount represents a high cost of capital. The unsecured nature and relatively short maturity tied to a future larger raise suggest a near-term need for significant additional funding under potentially challenging terms, indicating underlying financial pressure.

Positives

• Secured $2,000,000 in immediate funding for the Company's operations.
• The Note carries a 0% stated interest rate, which is favorable for the Company's cash flow management.
• The Company retains the option to prepay the Note in full or in part without penalty.
• The flexible maturity date, tied to a future significant capital raise, indicates a strategic plan for subsequent funding.

Negatives

• The Note was issued at a 20% original issue discount, meaning the Company received $2,000,000 for a $2,500,000 principal obligation, representing a high effective cost of capital.
• The unsecured nature of the Note means it is not backed by specific assets, potentially increasing risk for the holder but also reflecting the Company's asset profile.
• The relatively short maturity date (June 30, 2026) or earlier upon a $10M capital raise suggests a near-term need for additional significant funding.

Risks

• **Default Risk**: The Company faces an Event of Default if it fails to pay the Note Balance on the Maturity Date.
• **Bankruptcy/Insolvency Risk**: Voluntary or involuntary bankruptcy or insolvency proceedings would trigger an Event of Default, making the Note immediately due and payable.
• **Performance Default**: Failure to observe or perform any covenant, representation, warranty, condition, or agreement under the Note, if not remedied within 15 calendar days of written notice, constitutes an Event of Default.
• **Liquidity Risk**: The maturity date being tied to a future $10,000,000 capital raise implies a reliance on successful future fundraising to repay this Note. Failure to secure this funding by June 30, 2026, would require repayment from other sources.
• **Dilution Risk (Implied)**: The maturity date being tied to a future equity raise of $10M suggests that future dilution for existing shareholders is likely.

Future Outlook

The Company anticipates a future capital raise of at least $10,000,000, which would trigger the early maturity of this promissory note. This suggests a strategic plan for significant future funding to support its operations.

Management Comments

• The terms and conditions of the Note were determined as a result of arms-length negotiations.

Industry Context

This debt financing event is typical for a biotechnology company like Rein Therapeutics, which often relies on external capital to fund research, development, and operational expenses. The private placement nature is common for early-stage or growth-stage companies seeking specific institutional investors. The structure of the note, particularly the original issue discount and the maturity tied to a future capital raise, suggests it serves as bridge financing to sustain operations until a larger, more definitive funding round can be secured.

Comparison to Industry Standards

• The 20% original issue discount is a significant cost of capital, potentially higher than typical senior secured debt but often seen in bridge financing for early-stage biotech companies that may have limited revenue or tangible assets.
• The 0% stated interest rate is favorable for the company's immediate cash flow, but the OID effectively acts as a pre-paid yield for the investor, similar to other high-yield, short-term debt instruments in the sector.
• The unsecured nature of the note is common for companies with limited tangible assets, particularly in the biotech sector where intellectual property and pipeline assets are primary value drivers.
• The maturity tied to a future capital raise is a standard feature of bridge notes, designed to provide interim funding until a larger, more definitive financing round (often equity) can be completed, a common practice among development-stage biotech firms.

Stakeholder Impact

• **Shareholders**: Potential future dilution from the anticipated $10,000,000 capital raise, which is expected to be an equity issuance. The high cost of this bridge financing (20% OID) could also be seen as a negative for shareholder value.
• **Creditors**: The new note adds to the Company's debt obligations, though it is unsecured, placing it lower in the capital structure than secured debt.
• **Company Operations**: Provides immediate working capital ($2,000,000) to fund ongoing operations and development, which is crucial for a biotech company.

Next Steps

• The Company will issue a press release and/or file a Current Report on Form 8-K by 9:00 a.m. New York City time on the first business day following January 15, 2026, disclosing the material terms of the transaction.
• The Company plans to pursue a future capital raise of at least $10,000,000, which would trigger the early maturity of this Note.
• Maintain listing and trading of Common Stock on the Nasdaq Capital Market and comply with Nasdaq rules.

Key Dates

Recommendation

The company secured necessary bridge financing, which is a positive for immediate liquidity and continued operations. However, the 20% original issue discount represents a high cost of capital, and the unsecured nature of the note, coupled with its short maturity tied to a future $10 million capital raise, signals potential financial strain and likely future dilution for existing shareholders. Investors should hold to observe the terms and success of the anticipated larger capital raise and the company's progress in its core business before making further investment decisions.

Keywords

Rein Therapeutics, Promissory Note, Unsecured Debt, Private Placement, Capital Raise, Funicular Funds, Original Issue Discount, SEC Filing, 8-K, Biotechnology, Financing